Grant: Alliance Grants
Université de Montréal
$45,000.00
Biomimetic Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Valve Disease
EF 2024-25
Résumé
Congenital heart valve defects are detected in nearly 40,000 infants born in the United States annually. The heart valve defect can range in severity, with about 25% of cases requiring immediate open-heart surgery to replace the valve or other heart defects. Currently, no surgical heart valve prosthesis meets infants' size, flow, and developmental needs. Options include mechanical, bioprosthetic, homograft, or autograft valves. However, the most commonly used valves, mechanical and bioprosthetic valves, are designed with adults in mind. Thus, surgeons must alter the structure of the valve in the operating room, effectively altering the hemodynamic profile and minimizing the flow potential. In addition, mechanical and bioprosthetic valves are stagnant, meaning that children often face patient-prosthesis mismatch and multiple operations due to their growth. In addition to lack of growth, mechanical valves require life-long anticoagulation medication, and bioprosthetic valves tend to undergo structural valve degeneration. In response to these challenges, we envision fabricating innovative pediatric pulmonary heart valves with remodeling capability. Such valves will combine state-of-the-art innovations in 3D (bio)printing, functional biomaterials, and fluid dynamics. This approach will have a significant clinical impact in advancing the traditional devices with the above-mentioned challenges to fabricate off-the-shelf pediatric pulmonary heart valves that can facilitate translation from bench to bedside. To enable this approach, we will integrate device engineering and advanced biofabrication technologies (e.g., 3D (bio)printing) with functional biomaterials engineering to allow the fabrication and validation of off-the-shelf pediatric heart valves with remodeling capacity. This approach will provide substantial outcomes for definitive product development in support of the 3D (bio)printed heart valve and generate data in support of an animal study for safety and efficacy validation (out of this project's scope).
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
586835-2023
Name nom
Savoji, Houman H
Department département
Génie biomédical, Institut de
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
45000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Biomimetic Pulmonary Heart Valve for the Treatment of Pediatric Congenital Heart Valve Disease
Keywords
3d (bio)printing; advanced biofabrication techniques; biomechanics; bioreactor; children; heart valves; hydrodynamics; in vitro evaluation; transcatheter pulmonary valve replac
Application summary
Congenital heart valve defects are detected in nearly 40,000 infants born in the United States annually. The heart valve defect can range in severity, with about 25% of cases requiring immediate open-heart surgery to replace the valve or other heart defects. Currently, no surgical heart valve prosthesis meets infants' size, flow, and developmental needs. Options include mechanical, bioprosthetic, homograft, or autograft valves. However, the most commonly used valves, mechanical and bioprosthetic valves, are designed with adults in mind. Thus, surgeons must alter the structure of the valve in the operating room, effectively altering the hemodynamic profile and minimizing the flow potential. In addition, mechanical and bioprosthetic valves are stagnant, meaning that children often face patient-prosthesis mismatch and multiple operations due to their growth. In addition to lack of growth, mechanical valves require life-long anticoagulation medication, and bioprosthetic valves tend to undergo structural valve degeneration. In response to these challenges, we envision fabricating innovative pediatric pulmonary heart valves with remodeling capability. Such valves will combine state-of-the-art innovations in 3D (bio)printing, functional biomaterials, and fluid dynamics. This approach will have a significant clinical impact in advancing the traditional devices with the above-mentioned challenges to fabricate off-the-shelf pediatric pulmonary heart valves that can facilitate translation from bench to bedside. To enable this approach, we will integrate device engineering and advanced biofabrication technologies (e.g., 3D (bio)printing) with functional biomaterials engineering to allow the fabrication and validation of off-the-shelf pediatric heart valves with remodeling capacity. This approach will provide substantial outcomes for definitive product development in support of the 3D (bio)printed heart valve and generate data in support of an animal study for safety and efficacy validation (out of this project's scope).